UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/447,227	11/22/1999	MARK C. SHULTS	DEXCOM.008DV1	3546
	7590 07/17/200 RTENS OLSON & BE	EXAMINER		
2040 MAIN ST		NASSER, ROBERT L		
FOURTEENTH FLOOR IRVINE, CA 92614			ART UNIT	PAPER NUMBER
			3735	
			NOTIFICATION DATE	DELIVERY MODE
			07/17/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jcartee@kmob.com eOAPilot@kmob.com

		Sic			
	Application No.	Applicant(s)			
	09/447,227	SHULTS ET AL			
Office Action Summary	Examiner	Art Unit			
·	Robert L. Nasser	3735			
The MAILING DATE of this communication app	,				
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO (36(a). In no event, however, may a reply be till will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE.	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on <u>02 №</u>	fav 2007				
	s action is non-final.				
3) Since this application is in condition for allowa		osecution as to the merits is			
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
_	re nending in the application				
4)☑ Claim(s) <u>33,34,38,41,42,48,49 and 54-83</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>33, 34, 38, 41, 42, 48, 49, 54-83</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requirement.				
Application Papers					
9) The specification is objected to by the Examine	er.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)☐ The oath or declaration is objected to by the Ex	kaminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
1) X Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D	ate			
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal F 6) Other:	-atent Application			

Art Unit: 3735

Claims 41 and 42 are objected to in that there is no antecedent basis for the implant.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 33, 34, 38, 41, 42, and 54-83 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gough et al 5985129 in view of Picha 5271736. Gough et al shows a wholly implantable glucose sensing method including wholly implanting a device in a host, where the device provides continuous glucose sensing and comprises a housing 10 having a protruding convexly curved portion (to the right in the figure) that has a different curvature than the housing, and a sensing membrane 16 on the tip of the protruding portion. It does not have the first domain. However, Picha teaches that it is known to encase an implanted sensor in a layer that is angiogenic or promotes vascularization, to enhance the measurement process, as described in columns 5 and 6. Hence, it would have been obvious to modify Gough to use such a layer, to improve the measurement process. Claim 42 is rejected in that the device telemetrically communicates data (see column 5, lines 60-65). Claims 54 and 55 are rejected in that there is an electrolytic phase 12. . With respect to claims 56-58 and 62, it is the examiner's position that given that the device of the combination has an angiogenic or vascular promoting layer, it would measure glucose accurately for the claimed time

Art Unit: 3735

periods. With respect to claims 59-61, applicant has admitted that it is known to explant the device when the useful life of the device is over. Claim 63 is rejected in that the foam of Picha is a silicone elastomer (see column 3, line 61). Claim 65 is rejected in that the device is an enzymatic sensor (see column 9, lines 5-10). With respect to claims 66-69 the examiner takes official notice that all of the sensors recited are known glucose sensors. Hence, it would have been obvious to modify Allen to use any of the recited sensors, as it is merely the substitution of one known equivalent sensor for another. Claims 70-83 are rejected for the reasons given above.

Claims 48 and 49 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gough et al in view of Picha, as applied to claims 33, 34, 38, 41, 42, and 54-83 above, and further in view of the Gilligan et al article entitled "Evaluation of a subcutaneous glucose model out to ... Gilligan further teaches using an enzyme membrane in a glucose sensor. As such, it would have been obvious to modify the combination to use an enzyme membrane, as it is merely the substitution of one equivalent sensor for another. In addition, the examiner takes official notice that glucose oxidase is well known and hence obvious to use in a glucose sensor as the enzyme.

Applicant's arguments filed 5/2/2007 have been fully considered but they are moot in view of the new grounds of rejection.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Art Unit: 3735

Pfeiffer et al 5640954 shows a partially implanted device with a housing 18 and a concave protrusion 50 with a different curvature than the housing.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert L. Nasser whose telephone number is 571 272-4731. The examiner can normally be reached on m-f 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Charles Marmor II can be reached on 571 272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3735

Page 5

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

Information regarding the status of an application may be obtained from the

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Robert L. Nasser **Primary Examiner** Art Unit 3735

RLN July 7, 2007

Lilvenans